2. Search Result
Search Result
Results for "

Hormone-dependent cancers

" in MedChemExpress (MCE) Product Catalog:

21

Inhibitors & Agonists

3

Peptides

3

Natural
Products

6

Isotope-Labeled Compounds

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13632
    Exemestane
    4 Publications Verification

    FCE 24304; EXE

    		 Cytochrome P450 Endocrinology Cancer
    Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane
  • HY-13632R
    Exemestane (Standard)
    4 Publications Verification

    FCE 24304(Standard); EXE (Standard)

    		 Cytochrome P450 Reference Standards Endocrinology Cancer
    Exemestane (Standard) is the analytical standard of Exemestane. This product is intended for research and analytical applications. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane (Standard)
  • HY-125209
    TH5427

    		DNA/RNA Synthesis Cancer
    TH5427 is a promising, targeted inhibitor that can be used to further study NUDT5 activity and ADP-ribose metabolism. TH5427, blocks progestin-dependent, PAR-derived nuclear ATP synthesis and subsequent chromatin remodeling, gene regulation and proliferation in breast cancer cells. NUDT5 is recently identified as a rheostat of hormone-dependent gene regulation and proliferation in breast cancer cells .
    TH5427
  • HY-176270
    ESC1002755

    		17β-HSD Neurological Disease Cancer
    ESC1002755 is a 17β-HSD10 inhibitor with an IC50 of 19 nM. ESC1002755 has significant enzyme specificity with non-/uncompetitive inhibition against the cofactor NADH. ESC1002755 shows minimal cytotoxicity towards the HEK293 at 50 μM. ESC1002755 is promising for Alzheimer’s disease and hormone-dependent cancers (such as prostate, bone and colorectal cancer) research .
    ESC1002755
  • HY-150542
    Steroid sulfatase-IN-2

    		Steroid Sulfatase Cancer
    Steroid sulfatase -IN-2 is an active steroid sulfatase (STS) inhibitor with an IC50 value of 109.5 nM. Steroid sulfatase-IN-2 can be used for the research of hormone-dependent cancers, such as estrogen-dependent breast and endometrial cancer .
    Steroid sulfatase-IN-2
  • HY-N8366
    Alloisoimperatorin

    		Phosphatase Endocrinology Cancer
    Alloisoimperatorin (Compound 5) is a phytoestrogen that can be isolated from Angelica dahurica. Alloisoimperatorin can induce alkaline phosphatase (AP) activity with an EC50 of 0.8 μg/mL. Alloisoimperatorin can be used in the study of hormone-dependent cancers and the alleviation of menopausal symptoms .
    Alloisoimperatorin
  • HY-13632S
    Exemestane-d2

    FCE 24304-d2; EXE-d2

    		 Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d2 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-d2
  • HY-13632S2
    Exemestane-d3

    FCE 24304-d3; EXE-d3

    		 Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d3 is the deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-d3
  • HY-13632S1
    Exemestane-13C3

    		Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane- 13C3 is the 13C-labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-13C3
  • HY-13632S6
    Exemestane-d4

    FCE 24304-d4; EXE-d4

    		 Isotope-Labeled Compounds Cytochrome P450 Endocrinology Cancer
    Exemestane-d4 (FCE 24304-d4) is deuterium labeled Exemestane. Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-d4
  • HY-13632S5
    Exemestane-13C,d2

    FCE 24304-13C,d2; EXE-13C,d2

    		 Cytochrome P450 Isotope-Labeled Compounds Endocrinology Cancer
    Exemestane- 13C,d2 is 13C and deuterated labeled Exemestane (HY-13632). Exemestane (FCE 24304) is a selective, irreversible and orally active steroidal aromatase inhibitor with IC50s of 30 nM and 40 nM for human placental and rat ovarian aromatase, respectively. Exemestane can be used for hormone-dependent breast cancer research .
    Exemestane-13C,d2
  • HY-125916
    Pseurotin A

    		Endogenous Metabolite Cancer
    Pseurotin A is a secondary metabolite of Aspergillus and other fungi. Pseurotin A is a competitive inhibitor of chitin synthase and a neuritogenic agent. Pseurotin A inhibits IgE production (IC50 = 3.6 μM). Pseurotin A inhibits the PCSK9-LDLr interaction. Pseurotin A shows dose-dependent reduction of PCSK9, along with increased LDLR levels in hormone-dependent breast cancer cell lines. Pseurotin A exhibits antitumor activity .
    Pseurotin A
  • HY-W267205
    3-Acetyl-7-Hydroxycoumarin

    		17β-HSD Endocrinology Cancer
    3-Acetyl-7-Hydroxycoumarin (Compound 2) is a high selective 17-beta-hydroxysteroid dehydrogenase type 1 (17β-HSD1) inhibitor. 3-Acetyl-7-Hydroxycoumarin shows a significant improvement of the inhibitory potency, with 57% inhibition of 17β-HSD1 at 6 μM. 3-Acetyl-7-Hydroxycoumarin is promising for research of hormone-dependent diseases, such as breast cancer and endometriosis .
    3-Acetyl-7-Hydroxycoumarin
  • HY-155535
    17β-HSD10-IN-2

    		17β-HSD Neurological Disease
    17β-HSD10-IN-2 (compound 11) is a benzothiazolylurea-based inhibitor，targeting to 17β-hydroxysteroid dehydrogenase type 10 (17β-HSD10)，a multifunctional mitochondrial enzyme. 17β-HSD10-IN-2 don't lead to mitochondrial off-targets and cytotoxic or neurotoxic effects. 17β-HSD10 inhibitors can be used for research in Alzheimer's disease (AD) and hormone-dependent cancer .
    17β-HSD10-IN-2
  • HY-P2161B
    TAK-683 acetate
    1 Publications Verification

    		 Kisspeptin Receptor Cancer
    TAK-683 acetate is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 acetate is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 acetate depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 acetate
  • HY-P2161
    TAK-683

    		Kisspeptin Receptor Cancer
    TAK-683 is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683
  • HY-P2161A
    TAK-683 TFA

    		Kisspeptin Receptor Cancer
    TAK-683 TFA is a potent full KISS1 receptor (KISS1R) agonist (IC50=170 pM) with improved metabolic stability. TAK-683 TFA is a nonapeptide metastin analog, exhibits agonistic activities to KISS1R with EC50 values of 0.96 nM and 1.6 nM for human and rat, respectively . TAK-683 TFA depletes GnRH in the hypothalamus and reduces plasma FSH, LH, and testosterone levels in vivo, it has the potential for the study of hormone-dependent prostate cancer .
    TAK-683 TFA
  • HY-16474
    Relugolix

    TAK-385

    		 GnRH Receptor Endocrinology Cancer
    Relugolix (TAK-385)?is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix
  • HY-16474S
    Relugolix-d6

    TAK-385-d6

    		 Isotope-Labeled Compounds GnRH Receptor Endocrinology Cancer
    Relugolix-d6 is deuterium labeled Relugolix. Relugolix (TAK-385)?is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix-d6
  • HY-16474R
    Relugolix (Standard)

    TAK-385 (Standard)

    		 Reference Standards GnRH Receptor Endocrinology Cancer
    Relugolix (Standard) is the analytical standard of Relugolix. This product is intended for research and analytical applications. Relugolix (TAK-385) is a potent, orally active, nonpeptidic gonadotropin-releasing hormone (GnRH) antagonist. Relugolix possesses high affinity and potent antagonistic activity for human receptor (binding IC50=0.33 nM) and monkey receptor (IC50=0.32 nM) compared with TAK-013 (HY-100209) . Relugolix is used for the study of sex-hormone-dependent diseases, such as including endometriosis, uterine fibroids and prostate cancer et al .
    Relugolix (Standard)
  • HY-149486
    FGFR1 inhibitor 7

    		FGFR Cancer
    FGFR1 inhibitor 7 (compound 5) is an inhibitor of FGFR1 Tyrosine Kinase with IC50 value of 0.33 nM. FGFR1 inhibitor 7 shows broad-spectrum cytotoxicity agasinst human cancer cell lines, and inhibits MOLT3 cells with IC50 of 2.1 μM .
    FGFR1 inhibitor 7

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: